Quick Takeaways
- BIIB - BIOGEN INC. has 31 insiders with reported activity on this page.
- Net insider value flow over the last year: -$1,363,178.
- Recent transaction rows are available for direct filing-level review.
- Info
- Significant Ownership
- Insider Ownership
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 31 Insiders of BIOGEN INC.
- Symbol
- BIIB on Nasdaq
- Location
- Cambridge, MA
What Changed
- Buy value: $152,144; sell value: $1,515,322.
- Net share flow: -8,716.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$1,363,178.
Buys
$152,144
Shares: 1,238
Insiders: 2
Sells
$1,515,322
Shares: 9,954
Insiders: 2
Net
-$1,363,178
Shares: -8,716
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 3 | 3,408 | $585 | $665,664 | -$665,079 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 517 | $0 | $69,045 | -$69,045 |
| 9-12 | 1,235 | 6,029 | $151,559 | $780,612 | -$629,053 |
BIOGEN INC. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Alexander J. Denner | Director | $163,208,552 | Mixed | 15 Jun 2022 | ||
| Michel Vounatsos | Chief Executive Officer, Director | $23,909,726 | Mixed | 18 Feb 2022 | ||
| Susan H. Alexander | EVP Chief Legal Officer | $11,981,713 | Mixed | 13 Feb 2026 | ||
| Stelios Papadopoulos | Director | $9,498,648 | Mixed | 15 Jun 2022 | ||
| Christopher A. Viehbacher | President and CEO, Director | $8,566,813 | Mixed | 13 Feb 2026 | ||
| Ginger Gregory | EVP, Human Resources | $4,498,136 | Mixed | 13 Feb 2026 | ||
| Mr. Chirfi Guindo | Head of Glob Prod Strat & Com | $4,139,728 | Mixed | 18 Feb 2022 | ||
| Caroline Dorsa | Director | $3,931,673 | +$151,559 | +4% | Mixed | 17 Jun 2025 |
| Nicole Murphy | Head of Pharm Ops and Tech | $3,824,839 | +$585 | +0.02% | Filing P/S | 12 Feb 2026 |
| Richard Mulligan | Director | $3,744,552 | Mixed | 15 Jun 2022 | ||
| Michael R. McDonnell | EVP, Chief Financial Officer | $3,469,566 | Mixed | 10 Feb 2025 | ||
| Nancy Leaming | Director | $3,413,224 | Mixed | 01 Jul 2021 | ||
| Eric K. Rowinsky | Director | $3,086,671 | Mixed | 17 Jun 2025 | ||
| Alfred Sandrock | Head of Research & Development | $2,521,940 | Mixed | 07 Jun 2021 | ||
| Robin Kramer | Chief Financial Officer | $2,307,886 | Mixed | 13 Feb 2026 | ||
| Rachid Izzar | Head of Global Product Strat. | $2,215,192 | -$300,105 | -12% | Mixed | 13 Feb 2026 |
| Brian S. Posner | Director | $1,990,200 | Mixed | 31 Dec 2022 | ||
| Stephen A. Sherwin | Director | $1,735,912 | Mixed | 17 Jun 2025 | ||
| Adam Keeney | Head of Corporate Development | $1,692,564 | Mixed | 13 Feb 2026 | ||
| Priya Singhal | Head of Development | $1,607,261 | -$1,215,217 | -43% | Filing P/S | 13 Feb 2026 |
| Alphonse Galdes | EVP Pharmaceutical Oper & Tech | $1,496,307 | Mixed | 19 Jan 2022 | ||
| Jesus B. Mantas | Director | $1,237,509 | Mixed | 17 Jun 2025 | ||
| Jane Grogan | Head of Research | $1,207,928 | Mixed | 13 Feb 2026 | ||
| William A. Hawkins III | Director | $1,123,625 | Mixed | 17 Jun 2025 | ||
| Maria C. Freire | Director | $864,278 | Mixed | 17 Jun 2025 | ||
| Susan K. Langer | Director | $650,472 | Mixed | 17 Jun 2025 | ||
| William D. /ca/ Jones | Director | $531,960 | Mixed | 15 Jun 2022 | ||
| Monish D. Patolawala | Director | $470,502 | Mixed | 17 Jun 2025 | ||
| Sean Godbout | Chief Accounting Officer | $317,878 | Mixed | 01 Apr 2026 | ||
| Lloyd Minor | Director | $300,563 | Mixed | 17 Jun 2025 | ||
| Menelas N. Pangalos | Director | $0 | Mixed | 17 Jun 2025 |
Top shareholders of BIOGEN INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
|
Company |
12%
|
17,447,092
|
$3,070,513,721 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
8.5%
from 13D/G
|
14,811,370
|
$2,606,652,919 | — | 31 Dec 2025 | |
| PRIMECAP MANAGEMENT CO/CA/ |
13F
13D/G
|
Company |
10%
from 13D/G
|
14,757,997
|
$2,597,259,895 | — | 31 Dec 2025 | |
| FMR LLC |
13F
13D/G
|
Company |
6.4%
from 13D/G
|
9,425,863
|
$1,658,857,459 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
13D/G
|
Company · STATE STREET CORPORATION |
5%
from 13D/G
|
7,159,020
|
$1,259,915,930 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.9%
|
4,199,399
|
$736,434,804 | — | 31 Dec 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2.4%
|
3,551,269
|
$624,987,832 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1.9%
|
2,813,192
|
$495,093,660 | — | 31 Dec 2025 | |
| NORGES BANK |
13F
|
Company |
1.8%
|
2,638,834
|
$464,408,396 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.6%
|
2,325,013
|
$409,179,635 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.3%
|
1,857,262
|
$326,859,629 | — | 31 Dec 2025 | |
| Boston Partners |
13F
|
Company |
1.2%
|
1,720,595
|
$302,815,433 | — | 31 Dec 2025 | |
| Invesco Ltd. |
13F
|
Company |
1.1%
|
1,655,441
|
$291,341,046 | — | 31 Dec 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
1%
|
1,528,616
|
$269,021,112 | — | 31 Dec 2025 | |
| Legal & General Group Plc |
13F
|
Company |
0.99%
|
1,459,597
|
$256,874,480 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.98%
|
1,446,126
|
$254,503,714 | — | 31 Dec 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.95%
|
1,391,370
|
$244,867,205 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.89%
|
1,305,007
|
$229,668,181 | — | 31 Dec 2025 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
0.8%
|
1,170,907
|
$206,068,000 | — | 31 Dec 2025 | |
| Pacer Advisors, Inc. |
13F
|
Company |
0.78%
|
1,145,890
|
$201,665,181 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.78%
|
1,143,902
|
$201,315,313 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.77%
|
1,128,845
|
$198,665,432 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.77%
|
1,125,586
|
$198,091,880 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.75%
|
1,099,366
|
$193,477,399 | — | 31 Dec 2025 | |
| VAN ECK ASSOCIATES CORP |
13F
|
Company |
0.72%
|
1,065,616
|
$187,538,000 | — | 31 Dec 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.7%
|
1,024,268
|
$180,260,925 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.65%
|
960,645
|
$169,066,216 | — | 31 Dec 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.65%
|
953,728
|
$167,846,591 | — | 31 Dec 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.64%
|
947,494
|
$166,900,232 | — | 31 Dec 2025 | |
| Alexander J. Denner |
3/4/5
|
Director |
—
class O/S missing
|
658,099
|
$163,208,552 | — | 15 Jun 2022 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.55%
|
811,106
|
$142,746,606 | — | 31 Dec 2025 | |
| FRED ALGER MANAGEMENT, LLC |
13F
|
Company |
0.54%
|
798,774
|
$140,576,236 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.54%
|
792,071
|
$139,397,000 | — | 31 Dec 2025 | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ |
13F
|
Company |
0.48%
|
712,559
|
$125,403,258 | — | 31 Dec 2025 | |
| Employees Provident Fund Board |
13F
|
Company |
0.48%
|
704,196
|
$123,931,454 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.45%
|
661,684
|
$116,449,767 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.44%
|
641,788
|
$112,948,272 | — | 31 Dec 2025 | |
| Robeco Institutional Asset Management B.V. |
13F
|
Company |
0.42%
|
610,908
|
$107,513,704 | — | 31 Dec 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.41%
|
607,953
|
$106,993,648 | — | 31 Dec 2025 | |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC |
13F
|
Company |
0.4%
|
588,545
|
$103,578,035 | — | 31 Dec 2025 | |
| Patient Capital Management, LLC |
13F
|
Company |
0.39%
|
576,352
|
$101,432,302 | — | 31 Dec 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.39%
|
573,844
|
$100,990,805 | — | 31 Dec 2025 | |
| Amundi |
13F
|
Individual |
0.39%
|
572,429
|
$100,741,780 | — | 31 Dec 2025 | |
| FIRST TRUST ADVISORS LP |
13F
|
Company |
0.38%
|
565,847
|
$99,583,415 | — | 31 Dec 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.37%
|
541,825
|
$95,356,000 | — | 31 Dec 2025 | |
| CAUSEWAY CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.35%
|
521,101
|
$91,708,545 | — | 31 Dec 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.35%
|
508,067
|
$89,414,711 | — | 31 Dec 2025 | |
| HSBC HOLDINGS PLC |
13F
|
Company |
0.34%
|
503,832
|
$88,838,130 | — | 31 Dec 2025 | |
| AustralianSuper Pty Ltd |
13F
|
Company |
0.32%
|
476,812
|
$83,914,144 | — | 31 Dec 2025 | |
| Zurcher Kantonalbank (Zurich Cantonalbank) |
13F
|
Company |
0.31%
|
452,442
|
$79,625,268 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for BIOGEN INC.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Sean Godbout | BIIB | Common Stock | Tax liability | -3.87% | -54 | 1,342 | 01 Apr 2026 | Direct | ||
| Sean Godbout | BIIB | Common Stock | Options Exercise | 14.9% | 181 | 1,396 | 01 Apr 2026 | Direct | ||
| Sean Godbout | BIIB | Restricted Stock Unit | Options Exercise | -33.2% | -181 | 364 | 01 Apr 2026 | Direct | ||
| Christopher A. Viehbacher | BIIB | Restricted Stock Unit | Award | 38,015 | 38,015 | 13 Feb 2026 | Direct | |||
| Priya Singhal | BIIB | Restricted Stock Unit | Award | 10,560 | 10,560 | 13 Feb 2026 | Direct | |||
| Nicole Murphy | BIIB | Restricted Stock Unit | Award | 10,560 | 10,560 | 13 Feb 2026 | Direct | |||
| Robin Kramer | BIIB | Restricted Stock Unit | Award | 8,450 | 8,450 | 13 Feb 2026 | Direct | |||
| Adam Keeney | BIIB | Restricted Stock Unit | Award | 8,025 | 8,025 | 13 Feb 2026 | Direct | |||
| Rachid Izzar | BIIB | Restricted Stock Unit | Award | 7,390 | 7,390 | 13 Feb 2026 | Direct | |||
| Jane Grogan | BIIB | Restricted Stock Unit | Award | 8,450 | 8,450 | 13 Feb 2026 | Direct | |||
| Ginger Gregory | BIIB | Restricted Stock Unit | Award | 8,025 | 8,025 | 13 Feb 2026 | Direct | |||
| Sean Godbout | BIIB | Restricted Stock Unit | Award | 1,800 | 1,800 | 13 Feb 2026 | Direct | |||
| Susan H. Alexander | BIIB | Restricted Stock Unit | Award | 8,450 | 8,450 | 13 Feb 2026 | Direct | |||
| Nicole Murphy | BIIB | Common Stock | Purchase | 0.02% | $585 | $195.04 | 3 | 19,611 | 12 Feb 2026 | Direct |
| Priya Singhal | BIIB | Common Stock | Sale | -24.8% | $531,548 | $199.83 | -2,660 | 8,043 | 09 Feb 2026 | Direct |
| Christopher A. Viehbacher | BIIB | Common Stock | Tax liability | -34.2% | -10,980 | 21,095 | 06 Feb 2026 | Direct | ||
| Christopher A. Viehbacher | BIIB | Common Stock | Options Exercise | 202.4% | 24,461 | 36,548 | 06 Feb 2026 | Direct | ||
| Christopher A. Viehbacher | BIIB | Restricted Stock Unit | Options Exercise | -73.1% | -24,461 | 9,009 | 06 Feb 2026 | Direct | ||
| Priya Singhal | BIIB | Common Stock | Tax liability | -24.9% | -2,468 | 7,432 | 06 Feb 2026 | Direct | ||
| Priya Singhal | BIIB | Common Stock | Options Exercise | 132.3% | 6,900 | 12,115 | 06 Feb 2026 | Direct | ||
| Priya Singhal | BIIB | Restricted Stock Unit | Options Exercise | -75.7% | -6,900 | 2,217 | 06 Feb 2026 | Direct | ||
| Nicole Murphy | BIIB | Common Stock | Tax liability | -17.9% | -3,339 | 15,307 | 06 Feb 2026 | Direct | ||
| Nicole Murphy | BIIB | Common Stock | Options Exercise | 71% | 8,725 | 21,016 | 06 Feb 2026 | Direct | ||
| Nicole Murphy | BIIB | Restricted Stock Unit | Options Exercise | -100% | -8,725 | 0 | 06 Feb 2026 | Direct | ||
| Robin Kramer | BIIB | Common Stock | Tax liability | -15.3% | -1,543 | 8,528 | 06 Feb 2026 | Direct | ||
| Robin Kramer | BIIB | Common Stock | Options Exercise | 66.4% | 5,003 | 12,535 | 06 Feb 2026 | Direct | ||
| Robin Kramer | BIIB | Restricted Stock Unit | Options Exercise | -100% | -5,003 | 0 | 06 Feb 2026 | Direct | ||
| Adam Keeney | BIIB | Common Stock | Tax liability | -30.6% | -1,583 | 3,597 | 06 Feb 2026 | Direct | ||
| Adam Keeney | BIIB | Common Stock | Options Exercise | 283% | 5,080 | 6,875 | 06 Feb 2026 | Direct | ||
| Adam Keeney | BIIB | Restricted Stock Unit | Options Exercise | -73.8% | -5,080 | 1,802 | 06 Feb 2026 | Direct | ||
| Rachid Izzar | BIIB | Common Stock | Tax liability | -21.6% | -2,038 | 7,399 | 06 Feb 2026 | Direct | ||
| Rachid Izzar | BIIB | Common Stock | Options Exercise | 140.7% | 6,889 | 11,786 | 06 Feb 2026 | Direct | ||
| Rachid Izzar | BIIB | Restricted Stock Unit | Options Exercise | -100% | -6,889 | 0 | 06 Feb 2026 | Direct | ||
| Jane Grogan | BIIB | Common Stock | Tax liability | -26.4% | -991 | 2,769 | 06 Feb 2026 | Direct | ||
| Jane Grogan | BIIB | Common Stock | Options Exercise | 235.4% | 3,258 | 4,642 | 06 Feb 2026 | Direct | ||
| Jane Grogan | BIIB | Restricted Stock Unit | Options Exercise | -70.2% | -3,258 | 1,385 | 06 Feb 2026 | Direct | ||
| Ginger Gregory | BIIB | Common Stock | Tax liability | -12.2% | -2,589 | 18,609 | 06 Feb 2026 | Direct | ||
| Ginger Gregory | BIIB | Common Stock | Options Exercise | 44% | 7,183 | 23,491 | 06 Feb 2026 | Direct | ||
| Ginger Gregory | BIIB | Restricted Stock Unit | Options Exercise | -100% | -7,183 | 0 | 06 Feb 2026 | Direct | ||
| Sean Godbout | BIIB | Common Stock | Tax liability | -34.7% | -359 | 676 | 06 Feb 2026 | Direct | ||
| Sean Godbout | BIIB | Common Stock | Options Exercise | 341.8% | 1,079 | 1,395 | 06 Feb 2026 | Direct | ||
| Sean Godbout | BIIB | Restricted Stock Unit | Options Exercise | -100% | -1,079 | 0 | 06 Feb 2026 | Direct | ||
| Susan H. Alexander | BIIB | Common Stock | Tax liability | -8.57% | -3,504 | 37,396 | 06 Feb 2026 | Direct | ||
| Susan H. Alexander | BIIB | Common Stock | Options Exercise | 26.4% | 9,046 | 43,321 | 06 Feb 2026 | Direct | ||
| Susan H. Alexander | BIIB | Restricted Stock Unit | Options Exercise | -100% | -9,046 | 0 | 06 Feb 2026 | Direct | ||
| Priya Singhal | BIIB | Common Stock | Sale | -10.7% | $134,116 | $179.30 | -748 | 6,271 | 02 Feb 2026 | Direct |
| Priya Singhal | BIIB | Common Stock | Tax liability | -7.66% | -582 | 7,019 | 30 Jan 2026 | Direct | ||
| Priya Singhal | BIIB | Common Stock | Options Exercise | 31.7% | 1,829 | 7,601 | 30 Jan 2026 | Direct | ||
| Priya Singhal | BIIB | Restricted Stock Unit | Options Exercise | -100% | -1,829 | 0 | 30 Jan 2026 | Direct | ||
| Christopher A. Viehbacher | BIIB | Common Stock | Tax liability | -17.2% | -3,404 | 16,443 | 01 Dec 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.